GC Biopharma scores FDA nod for immunoglobulin therapy Alyglo
South Korea’s GC Biopharma Corp. has gained U.S. FDA approval for its immune-deficiency plasma drug, Alyglo (immune globulin intravenous, human-stwk; IVIG-SN 10%), five months after refiling its BLA, five months after refiling its BLA and before its PDUFA date of Jan. 13, 2024.
Korea Gc Biopharma Corp South Korea Gc Biopharma Corp Immunoglobulin Therapy Ivig Sn 10 Green Cross Corp
Source: bioworld.com